Harnessing bi-exosome combination alleviates osteoarthritis progression

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Osteoarthritis Research

Background:

• Osteoarthritis (OA) poses a significant health challenge due to its increasing prevalence and complex pathogenesis.
• Current single-modality treatments struggle to provide comprehensive chondroprotection against OA.
• Exosomes derived from different cell sources exhibit distinct miRNA profiles, suggesting potential for targeted therapeutic strategies.

Purpose of the Study:

• To develop a novel bi-exosome combination therapy for osteoarthritis (OA).
• To investigate the combined anti-inflammatory and anti-catabolic effects of bone marrow mesenchymal stromal cell-derived exosomes (BMSC-Exo) and cartilage progenitor cell-derived exosomes (CPC-Exo).
• To evaluate the efficacy of this bi-exosome strategy in alleviating OA progression by modulating macrophage polarization and chondrocyte phenotype.

Main Methods:

• RNA sequencing was used to identify distinct miRNA enrichments in BMSC-Exo and CPC-Exo.
• A bi-exosome combination therapy was formulated using hyaluronic acid methacryloyl microspheres for delivery into the rat knee joint cavity.
• The effects of the bi-exosome combination on joint inflammation, catabolic environment, macrophage polarization, and chondrocyte phenotype were assessed.

Main Results:

• The bi-exosome combination therapy significantly postponed OA progression in a rat model.
• The treatment effectively combatted the joint inflammatory and catabolic environment associated with OA.
• Key molecular pathways, including miR-708-5p/NRP-1, miR-431/BRCA-1/PLK-1, and miR-7a-5p/NOTCH-3, were identified as dominant interventive targets.

Conclusions:

• Tailoring exosome compositions offers a promising multitargeting strategy for OA treatment.
• The developed bi-exosome combination therapy demonstrates potential for alleviating osteoarthritis progression.
• This approach highlights the therapeutic potential of combining BMSC-Exo and CPC-Exo for managing OA.